Filter by Category: In Vitro Activity
Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016)
Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016), Lead author: Duncan LR, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #333
Telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2014).
Telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2014). by Duncan LR, Sader HS, Smart JI, Flamm RK and Mendes RE published in J. Glob. Antimicrob. Resist.2017; 10: 271-276
Activity of dalbavancin tested against gram-positive clinical isolates causing skin and skin structure infections in paediatric patients from US hospitals (2014 – 2015).
Activity of dalbavancin tested against gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014 – 2015). by Pfaller MA, Mendes RE, Sader HS, Castanheira M and Flamm RK published in J. Glob. Antimicrob. Resist. 2017; 11: 4-7
In vitro activity of telavancin against clinically important gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions.
In vitro activity of telavancin against clinically important gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions. by Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI and Mendes RE published in Microb. Drug Resist., 2017; 23 (6): 718-726
In vitro activity of linezolid against clinically important gram-positive cocci in the United States: A 5-year summary of in vitro activity and resistance mechanisms from the LEADER Surveillance Program (2011-2015).
In vitro activity of linezolid against clinically important gram-positive cocci in the United States: A 5-year summary of in vitro activity and resistance mechanisms from the LEADER Surveillance Program (2011-2015). by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (7): e00609
In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two Phase 3 Studies of acute bacterial skin and skin structure infections (ABSSSI).
In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two Phase 3 Studies of acute bacterial skin and skin structure infections (ABSSSI). by McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C and Cammarata S published in Antimicrob. Agents Chemother. 2017; 61 (9): e007722017
Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria.
Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria. by Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (7): e00468-17
Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012-2014.
Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012-2014. by Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN and Sader HS published in Pediatr. Infect. Dis. J. 2017; 36 (5): 486-491
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Glob. Antimicrob. Resist. 2017; 8: 28-32
Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/beta-lactam combinations.
Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/beta-lactam combinations. by McLeod SM, Patey SA, Huband MD and Nichols WW published in Int. J. Antimicrob. Agents. 2017; 49 (4): 437-442